Emerging Drug Developer: GlobeImmune
Platform companies that can show promise against a number of diseases have been flourishing, and GlobeImmune is at a critical point in its effort to join that crowd. With a second therapy slated to start a mid-stage trial and an important set of data scheduled to land next year, the Colorado biotech is one short, but vitally important, step away from a juncture that could well spawn new business opportunities. A fresh funding round will take it through 2008, and into a new phase of development. Article